Montelukast

Montelukast, the active ingredient in Montelukast, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is employed in the maintenance treatment of asthma, relief of allergic rhinitis symptoms, and prevention of exercise‑induced bronchoconstriction in appropriate patients.

GNH USA supplies Montelukast as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and providing reliable global logistics for consistent product availability and comprehensive regulatory compliance support.

Montelukast is a leukotriene receptor antagonist used to manage several allergic and respiratory conditions. - Asthma: reduces frequency of asthma attacks and improves overall disease control. - Allergic rhinitis: alleviates nasal congestion, sneezing, itching and rhinorrhea. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast may cause a range of adverse reactions.

Common Side Effects: - Headache - Abdominal pain - Cough - Nasopharyngitis

Serious or Rare Side Effects: - Mood changes, including depression or suicidal thoughts - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Angioedema or severe allergic reactions

When prescribing Montelukast, consider the following safety measures. - Assess asthma control before initiating therapy: ensure baseline stability. - Monitor for neuropsychiatric events: watch for mood swings, depression, or suicidal ideation. - Use caution in patients with hepatic impairment: dose adjustment may be required. - Review concomitant medications for potential interactions that could alter exposure. - Store at ambient temperature: keep in the original pack, protect from moisture.

Montelukast can interact with several medicines; awareness helps maintain therapeutic effectiveness.

Major Interactions (Avoid): - Rifampin: strong enzyme inducer that lowers montelukast plasma levels. - Phenobarbital: induces metabolism, reducing drug exposure. - Carbamazepine: enzyme induction may decrease efficacy. - St. John’s wort: herbal inducer that can reduce montelukast concentrations.

Moderate Interactions (Monitor Closely): - Fluconazole: moderate CYP inhibition may increase exposure. - Erythromycin: can modestly raise montelukast levels. - Warfarin: monitor INR as montelukast may affect anticoagulation control.